{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:34:14Z","timestamp":1769920454260,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Cancer Center Research and Development Funds","award":["26-A-4"],"award-info":[{"award-number":["26-A-4"]}]},{"name":"National Cancer Center Research and Development Funds","award":["29-A-3"],"award-info":[{"award-number":["29-A-3"]}]},{"name":"National Cancer Center Research and Development Funds","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Funds","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H23Gann-012"],"award-info":[{"award-number":["H23Gann-012"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10147-023-02361-7","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T18:02:15Z","timestamp":1686160935000},"page":"1063-1072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Definitive S-1\/mitomycin-C chemoradiotherapy for stage II\/III anal canal squamous cell carcinoma: a phase I\/II dose-finding and single-arm confirmatory study (JCOG0903)"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5589","authenticated-orcid":false,"given":"Yoshinori","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Mizoguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kodaira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ohue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Teraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kinouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Iinuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Saida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihide","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Colorectal Cancer Study Group of the Japan Clinical Oncology Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7\u201334","journal-title":"CA Cancer J Clin"},{"key":"2361_CR2","volume-title":"Cancer statistics in Japan 2018","author":"T Hotta","year":"2018","unstructured":"Hotta T (2018) Cancer statistics in Japan 2018. Foundation for Promotion of Cancer Research, Tokyo"},{"key":"2361_CR3","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"UKCCCR Anal Cancer Working Party","year":"1996","unstructured":"UKCCCR Anal Cancer Working Party (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. Lancet 348:1049\u20131054","journal-title":"Lancet"},{"key":"2361_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefi Ore D et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I). Br J Cancer 102:1123\u20131128","journal-title":"Br J Cancer"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 15:2040\u20132049","journal-title":"J Clin Oncol"},{"key":"2361_CR6","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527\u20132539","journal-title":"J Clin Oncol"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"199","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL et al (2008) Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA 199:1914\u20131921","journal-title":"JAMA"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","volume":"30","author":"LL Gunderson","year":"2012","unstructured":"Gunderson LL, Winter KA, Ajani JA et al (2012) Long-term update of U.S. GI Intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluoruracil\/cisplatin. J Clin Oncol 30:4344\u20134351","journal-title":"J Clin Oncol"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol 14:516\u2013524","journal-title":"Lancet Oncol"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10147-009-0892-5","volume":"14","author":"A Takashima","year":"2009","unstructured":"Takashima A, Shimada Y, Hamaguchi T et al (2009) Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol 14:416\u2013420","journal-title":"Int J Clin Oncol"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063\u20131069","journal-title":"Lancet Oncol"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1111\/j.1349-7006.2008.00943.x","volume":"99","author":"L Zeng","year":"2008","unstructured":"Zeng L, Ou G, Itasaka S et al (2008) TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 99:2327\u20132335","journal-title":"Cancer Sci"},{"key":"2361_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/jjco\/hyr028","volume":"41","author":"A Takashima","year":"2011","unstructured":"Takashima A, Shimada Y, Hamaguchi T et al (2011) A Phase I\/II trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II\/III squamous cell carcinoma of anal canal (JCOG0903: SMART-AC). Jpn J Clin Oncol 41:713\u2013717","journal-title":"Jpn J Clin Oncol"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/cas.12764","volume":"106","author":"M Tahara","year":"2015","unstructured":"Tahara M, Fuse N, Mizusawa J et al (2015) Phase I\/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II\/III esophageal carcinoma (JCOG 0604). Cancer Sci 106:1414\u20131420","journal-title":"Cancer Sci"},{"key":"2361_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/CAD.0b013e3282f46ad8","volume":"19","author":"SH Park","year":"2008","unstructured":"Park SH, Kim YS, Hong J et al (2008) Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drugs 19:303\u2013307","journal-title":"Anticancer Drugs"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","volume":"18","author":"R Glynne-Jones","year":"2017","unstructured":"Glynne-Jones R, Sebag-Montefiore D, Meadows HM et al (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 18:347\u2013356","journal-title":"Lancet Oncol"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","volume":"72","author":"R Glynne-Jones","year":"2008","unstructured":"Glynne-Jones R, Meadows H, Wan S et al (2008) EXTRA\u2013a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 72:119\u2013126","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2361_CR18","unstructured":"National Comprehensive Cancer Network (NCCN) Clinical Practice guidelines in oncology. Anal carcinoma 2021; Version 1. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/anal.pdf. Accessed 10 May 2021"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:446\u2013453","journal-title":"Lancet Oncol"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","volume":"28","author":"PA Ott","year":"2017","unstructured":"Ott PA, Piha-Paul SA, Munster P et al (2017) Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 28:1036\u20131041","journal-title":"Ann Oncol"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919\u20131929","journal-title":"N Engl J Med"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342\u20132350","journal-title":"N Engl J Med"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"L Kachnic","year":"2013","unstructured":"Kachnic L, Winter K, Myerson R et al (2013) RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86:27\u201333","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02361-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T07:10:59Z","timestamp":1690787459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02361-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02361-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"1 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tetsuya Hamaguchi has received honoraria and research funding from Taiho Pharmaceutical. All other authors have no disclosures to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the Protocol Review Committee of JCOG and the institutional review board at each institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}